Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Globe Newswire•11/08/2026•08:15 ET
0
Whiz Insights
Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo’s investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); further updates expected by year-end 2026
Get started
Create a free account to read the full story.